Back to Endocrinology
Endocrinologyv2021Evidence-Based

International Diabetes Federation-Diabetes and Ramadan Alliance (IDF-DAR) Fasting Risk Assessment

Stratifies risk of fasting during Ramadan in diabetic patients using validated clinical parameters. The IDF-DAR tool provides evidence-based guidance for healthcare providers and patients to make informed decisions about the safety of fasting during Ramadan based on diabetes type, glycemic control, complications, and other risk factors.

Clinical Input Parameters

years
%
hours
Clinical Assessment
Awaiting Parameters
risk score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International Diabetes Federation-Diabetes and Ramadan Alliance (IDF-DAR) Fasting Risk Assessment is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within endocrinology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Risk Score = Diabetes Type + Years Since Diagnosis + Hypoglycemia Score + HbA1c Score + Treatment Score + Monitoring Score + Complication Scores + Social Factors

Clinical Pearls & Practice Notes

  • The IDF-DAR tool was developed through international consensus and validated across multiple populations
  • Fasting during Ramadan is a personal decision that should involve patient preference and medical guidance
  • Patients in all risk categories should receive pre-Ramadan education on glucose monitoring and symptom recognition
  • Medication timing adjustments may be necessary regardless of risk category
  • Emergency action plans should be established for all patients who choose to fast
  • Regular medical follow-up is essential during Ramadan fasting period

Evidence & Literature Citations

  1. Hassanein M, Sahay BK, Hafidh K, Djaballah K, Li H, Rahim MA, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract. 2022 Mar;185:109185. doi: 10.1016/j.diabres.2021.109185.
  2. Ibrahim M, Al Magd MA, Annabi FA, Assaad-Khalil S, Ba-Essa EM, Fahdil I, et al. Recommendations for management of diabetes during Ramadan: update 2020, applying evidence from a decade of research. BMJ Open Diabetes Res Care. 2020 May;8(1):e001248. doi: 10.1136/bmjdrc-2020-001248.
  3. Alam F, Oubari S, Ahmad J, Eba-Alkhayri A, Almadani A, Babineaux S, et al. Validity of the International Diabetes Federation risk stratification score of Ramadan fasting in individuals with diabetes mellitus. Saudi Med J. 2024 Jan;45(1):86-92. doi: 10.15537/smj.2024.45.1.20230497.

Score Interpretation Ranges

Low Risk0 – 3 pts

Fasting probably safe

Moderate Risk3.5 – 6 pts

Fasting safety uncertain

High Risk6.5 – 20 pts

Fasting probably unsafe

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.